125 related articles for article (PubMed ID: 33862415)
1. Inverse correlation between PD-L1 expression and LGR5 expression in tumor budding of stage II/III colorectal cancer.
Sato K; Uehara T; Nakajima T; Iwaya M; Miyagawa Y; Watanabe T; Ota H
Ann Diagn Pathol; 2021 Jun; 52():151739. PubMed ID: 33862415
[TBL] [Abstract][Full Text] [Related]
2. Correlation of clinicopathological features and LGR5 expression in colon adenocarcinoma.
Sato K; Uehara T; Iwaya M; Nakajima T; Miyagawa Y; Ota H; Tanaka E
Ann Diagn Pathol; 2020 Oct; 48():151587. PubMed ID: 32829068
[TBL] [Abstract][Full Text] [Related]
3. Correlation of clinicopathological features and LGR5 expression in colon adenocarcinoma.
Sato K; Uehara T; Iwaya M; Nakajima T; Miyagawa Y; Suga T; Ota H; Tanaka E
Ann Diagn Pathol; 2019 Jun; 40():161-165. PubMed ID: 31100646
[TBL] [Abstract][Full Text] [Related]
4. The role of tumor budding in colorectal adenocarcinoma: Possible involvement of the intestinal cancer stem cell marker Lgr5.
Sadek SA; A Rehim DM; Fatima S
Indian J Pathol Microbiol; 2020; 63(1):32-37. PubMed ID: 32031119
[TBL] [Abstract][Full Text] [Related]
5. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer.
Koganemaru S; Inoshita N; Miura Y; Miyama Y; Fukui Y; Ozaki Y; Tomizawa K; Hanaoka Y; Toda S; Suyama K; Tanabe Y; Moriyama J; Fujii T; Matoba S; Kuroyanagi H; Takano T
Cancer Sci; 2017 May; 108(5):853-858. PubMed ID: 28267224
[TBL] [Abstract][Full Text] [Related]
7. LGR5 expression is associated with prognosis in poorly differentiated gastric adenocarcinoma.
Ehara T; Uehara T; Nakajima T; Kinugawa Y; Kobayashi S; Iwaya M; Ota H; Soejima Y
BMC Cancer; 2021 Mar; 21(1):228. PubMed ID: 33676447
[TBL] [Abstract][Full Text] [Related]
8. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Expression in Colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition.
Secinti IE; Ozgur T; Dede I
Am J Clin Pathol; 2022 Oct; 158(4):506-515. PubMed ID: 35938631
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
Ko YS; Pyo JS
Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of leucine-rich-repeat-containing G-protein-coupled receptor 5, an intestinal stem cell marker, in gastric carcinomas.
Jang BG; Lee BL; Kim WH
Gastric Cancer; 2016 Jul; 19(3):767-77. PubMed ID: 26386561
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in colorectal adenocarcinoma.
Miskad UA; Hamzah N; Cangara MH; Nelwan BJ; Masadah R; Wahid S
Minerva Med; 2020 Aug; 111(4):337-343. PubMed ID: 33032394
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
[TBL] [Abstract][Full Text] [Related]
17. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Noh BJ; Kwak JY; Eom DW
BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Overexpression on Tumor-Infiltrating Lymphocytes Related to Better Prognosis of Colorectal Cancer.
Wang JL; Yu T; Sun TT; Feng Y; Xiong H; Fang JY
Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337839
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
20. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Schalper KA; Velcheti V; Carvajal D; Wimberly H; Brown J; Pusztai L; Rimm DL
Clin Cancer Res; 2014 May; 20(10):2773-82. PubMed ID: 24647569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
